EUCTR2007-004151-11-ES进行中（未招募）1 期
Estudio fase 2 aleatorizado, abierto y multicéntrico de Velcade y Fludarabina en comparación con Rituximab y Fludarabina en sujetos con linforma folicular previamente tratados con Rituximab.A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Subjects Previously Treated With Rituximab
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Potential subjects must satisfy the following criteria to be enrolled in the study:
- •?Male or female subjects 18 years or older
- •?Histologically proven diagnosis of follicular non-Hodgkin?s lymphoma grades 1or 2 according to the World Health Organization classification 41
- •?Subjects must have received at least 14 doses (375mg/m2 or appropriately adjusted dose) of rituximab for the treatment of this lymphoma as single agent rituximab or in rituximab-containing regimens as documented in the subject?s medical record
- •?Documented relapse or progression following last antineoplastic treatment
- •?At least 1 measurable tumor mass (>=1.5 cm x >=1.0 cm)
- •?Eastern Cooperative Oncology Group [ECOG] performance status =<2 (Attachment 1)
- •?Absolute neutrophil count (ANC) >=1.2 x 109 cells/L
- •?Platelets >=100 x 109 cells/L (subjects should not have received platelet transfusion in the preceding 7 days)
- •?Alanine aminotransferase =<2.5 x upper limit of normal (ULN)
- •?Aspartate aminotransferase =<2.5 x ULN
- •?Total bilirubin =<1.5 x ULN
- •?Measured or calculated creatinine clearance >70 mL/min (see Attachment 2 for the Cockcroft-Gault formula )
- •?To participate in the pharmacogenomic component of this study, subjects (or their legally acceptable representative) must have signed the informed consent form for pharmacogenomic research indicating willingness to participate in the pharmacogenomic component of the study (where local regulations permit)
- •?Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and have a negative serum beta-hCG pregnancy test at screening
- •?Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •?Subjects with histological or clinical transformation to an aggressive lymphoma
- •?History of disallowed therapies:
- •?prior treatment with VELCADE or fludarabine.
- •?antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization
- •?nitrosoureas within 6 weeks before randomization
- •?radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization
- •?major surgery within 3 weeks before randomization
- •?chronic use of corticosteroids, such as dexamethasone Note: Prednisone =<15 mg per day or its equivalent is allowed
- •?Peripheral neuropathy or neuropathic pain of Grade 2 or worse
- •?Diagnosed or treated for a malignancy other than NHL except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, DCIS of the breast, or other solid tumors curatively treated with no evidence of disease for >5 years
- •?Active systemic infection requiring treatment. Hepatitis carriers are not excluded from this study. However, hepatitis carriers should be carefully monitored during treatment for any signs of active hepatitis infection and treatment promptly stopped if active hepatitis disease is observed.
- •?Active central nervous system lymphoma. Brain MRI is required only if clinically indicated
- •?Recently received (within the past 6 months) a live virus vaccine
- •?History of allergic reaction attributable to compounds containing boron, mannitol, rituximab, or similar agents
- •?Serious medical conditions (such as severe hepatic impairment, pericardial disease, acute diffuse infiltrative pulmonary disease, systemic infections, etc) or psychiatric illness likely to interfere with participation in this clinical study
- •?Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is not excluded.
研究者
相似试验
进行中（未招募）
1 期
Estudio fase II, aleatorizado, abierto, multicéntrico para evaluar la seguridad e inmunogenicidad de la vacuna experimental adyuvada de gripe pandémica H1N1 administrada como primovacunación y booster en niños entre 6 y 35 meses de edad. - FLU D-PAN H1N1-009Inmunización de niños sanos de 6 a 35 meses frente a la nueva gripe H1N1 con potencial pandémico.EUCTR2009-013783-39-ESGlaxoSmithKline SA157
进行中（未招募）
1 期
Estudio fase II, abierto, aleatorizado, multicéntrico de Pazopanib (GW786034) en combinación con Lapatinib (GW572016) comparado con Pazopanib monoterapia y con Lapatinib en monoterapia en sujetos con cáncer cervical recurrente o persistente o estadío IVB según FIGO que hayan recibido uno o ningún tratamiento previo con quimioterapia para la enfermedad avanzada o recurrente.EUCTR2006-000236-27-ESGlaxoSmithKline S.A.
进行中（未招募）
不适用
Estudio en fase 2, abierto, multicéntrico y aleatorizado para evaluar la seguridad y la eficacia de cisplatino y pemetrexed con o sin cixutumumab como tratamiento de primera línea en pacientes con carcinoma de pulmón no microcítico avanzado, de histología no escamosaAn Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First Line Therapy in Patients with Advanced Nonsquamous Non Small Cell Lung Carcinomacarcinoma de pulmón no microcítico avanzado, de histología no escamosaMedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2010-022674-14-ESilly S.A.220
进行中（未招募）
不适用
Estudio de fase II, multicéntrico, abierto, aleatorizado, de tratamiento secuencial con docetaxel y erlotinib intermitente frente a erlotinib en pacientes con carcinoma no microcítico de pulmón localmente avanzado o metastásico tras fallo a un tratamiento quimioterápico previoEUCTR2008-007644-34-ESAsociación Terapeutica en Hematologia y Oncología Médicas
进行中（未招募）
不适用
Estudio de fase II, aleatorizado, abierto y multicéntrico, que compara el tratamiento con bevacizumab más RAD001 frente a interferón alfa-2a más bevacizumab en el tratamiento de primera línea de pacientes con carcinoma renal metastásico de células clarasA randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidneyPacientes con carcinoma renal metastásico de células clarasPatients with metastatic clear cell carcinoma of the kidneyMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2008-000077-38-ESovartis Farmacéutica S.A360